Skip to Content
Merck

P4365

PJ-34 hydrochloride hydrate

≥98% (HPLC), powder

Synonym(s):

PARP Inhibitor VIII, PJ 34 HCl, N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-(N,N-dimethylamino)acetamide hydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C17H17N3O2 · HCl · xH2O
CAS Number:
344458-15-7
Molecular Weight:
331.80 (anhydrous basis)
UNSPSC Code:
12352200
PubChem Substance ID:
24898531
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

PJ-34 hydrochloride hydrate, ≥98% (HPLC), powder

SMILES string

Cl[H].[H]O[H].CN(C)CC(=O)Nc1ccc2NC(=O)c3ccccc3-c2c1

InChI

1S/C17H17N3O2.ClH.H2O/c1-20(2)10-16(21)18-11-7-8-15-14(9-11)12-5-3-4-6-13(12)17(22)19-15;;/h3-9H,10H2,1-2H3,(H,18,21)(H,19,22);1H;1H2

InChI key

YCALIZUKAFUQCH-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to yellow

solubility

H2O: 22 mg/mL

Quality Level

100

Related Categories

Application

PJ-34 hydrochloride hydrate has been used:
  • as a poly(ADP-ribose) polymerase (PARP) inhibitor 1 in rats to test the effect of PAPR1 in neuropathic pain
  • as a component of protein extraction buffer to enable visualization of the high-molecular-weight smear of PARylated proteins in various cell samples
  • as PARP inhibitor in murine MLE-12 epithelial cell line

Biochem/physiol Actions

PJ-34 is a potent poly(ADP-ribose) polymerase (PARP) inhibitor.
PJ-34 is a prototypic poly(ADP-ribose) polymerase 1 (PARP-1) inhibitor.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

P4365-VAR: + P4365-IP: + P4365-BULK: + P4365-5MG:

jan

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000174914
0000174914
0000113076
0000069854
0000015950

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hai-yan Li et al.
Acta pharmacologica Sinica, 35(4), 496-503 (2014-03-19)
Daidzein (4',7-dihydroxyisoflavone) is an isoflavone exiting in many herbs that has shown anti-inflammation activity. The aim of this study was to investigate the mechanism underlying its anti-inflammatory action in murine lung epithelial cells. C57BL/6 mice were intranasally exposed to TNF-α
Garcia Soriano F et al.
Nature medicine, 7(1), 108-113 (2001-01-03)
Diabetic patients frequently suffer from retinopathy, nephropathy, neuropathy and accelerated atherosclerosis. The loss of endothelial function precedes these vascular alterations. Here we report that activation of poly(ADP-ribose) polymerase (PARP) is an important factor in the pathogenesis of endothelial dysfunction in
Yan Gao et al.
Brain, behavior, and immunity, 88, 482-496 (2020-04-14)
Emerging evidence has implicated poly-(ADP-ribose) polymerase 1 (PARP-1), a transcriptional coregulator, in a variety of inflammatory diseases. In the current study, the role of PARP-1 in neuropathic pain and the underlying mechanisms were investigated. Neuropathic pain was determined by assessing
G E Abdelkarim et al.
International journal of molecular medicine, 7(3), 255-260 (2001-02-17)
Focal cerebral ischemia activates the nuclear protein poly(ADP-ribose) polymerase (PARP) by single DNA strand breaks which leads to energy depletion and cell necrosis. Deletion or inhibition of PARP protects against ischemic brain injury. Here we examined the neuroprotective effect of
Mohamad El Amki et al.
Molecular neurobiology, 55(12), 9156-9168 (2018-04-14)
Benefits from thrombolysis with recombinant tissue plasminogen activator (rt-PA) after ischemic stroke remain limited due to a narrow therapeutic window, low reperfusion rates, and increased risk of hemorrhagic transformations (HT). Experimental data showed that rt-PA enhances the post-ischemic activation of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service